Japan: Simafex gets go-ahead to supply Lipiodol until 2017
The Japanese Ministry of Health, Labor and Well-Being (MHLW) has renewed Simafex’s GMP* certificate for the manufacture of Lipiodol’s active ingredient.
Following the study of Simafex's process and Quality System, the Japanese authorities approved the renewal of the certificate for the manufacture of Lipiodol's active ingredient . This authorizes Simafex to commercialize the product in Japan until October 2017.
*GMP (Good Manufacturing Practice)